Bausch Health Companies Investor Conference Presentation Deck
Bausch Health 3Q21 Update
Bausch Pharma4
11
BAUSCH- Health
3Q21 Reported Revenue: (1%)
3Q21 Organic Revenue ¹,2: 0%
Bausch Health Revenue Breakdown
Diversified
Products
11%
Ortho Derm
7%
International Rx
13%
Salix
24%
BAUSCH Health
BAUSCH+ LOMB
Bausch + Lomb
45%
Executing Our Business Recovery from COVID-19
Total company organic revenue ¹,2 was flat vs. 3Q20
●
●
Unleashing Growth Drivers
Strong performance and recovery from leading brands:
XIFAXAN® reported revenue growth of 12% vs. 3Q20
TRULANCE® reported revenue growth of 14% vs. 3Q20
Ocuvite® + PreserVision® reported revenue growth of 4% vs. 3Q 20
LUMIFY® reported $28M in revenue in 3Q21 or reported revenue growth of
40% vs. 3Q20
●
●
●
3Q21 Headwinds: Strong year-over-year comparator due to
COVID-19 rebound across some international businesses in 3Q20
●
Strong cash flow: $564M of cash generated from operations (GAAP)
during 3Q21; $382M³ adjusted cash flows from operations (non-GAAP)¹
during 3Q21
Delivering on near-term R&D catalysts:
Statistically significant topline results from second Phase 3 trial of NOV036 in
dry eye disease associated with Meibomian gland dysfunction; expected NDA
filing to FDA in 1H22
Received FDA approval for XIPERE TM5; expected to launch 1022
●
1. See Slide 2 and Appendix for further non-GAAP information.
2. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.
3. Excludes legacy legal settlements (net of insurance recoveries), separation payments, separation-related payments, IPO payments and IPO-related payments and net cash provided by Amoun operating activities. In 3Q21, the
adjustment resulted in a decrease to Adjusted Cash from Operations in 3Q21, due to these insurance recoveries.
4.
The remainder of Bausch Health is referred to as "Bausch Pharma" and will assume a new name upon separation from the Company's eye health business, Bausch + Lomb. Bausch Pharma revenues, a non-GAAP metric, are
determined by subtracting Bausch + Lomb segment revenues for the applicable period from total Bausch Health revenues for the applicable period. See slide 2 and the Appendix for further non-GAAP information.
5. In 2019, the Company acquired an exclusive license from Clearside Biomedical, Inc. for the commercialization and development of XIPERETM in the United States and Canada.
6. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of NOV03 in the United States and Canada.View entire presentation